Hydroxypropyl betadex - Cloudbreak Pharma
Alternative Names: CBT-006; Hydroxypropyl beta cyclodextrin - Cloudbreak PharmaLatest Information Update: 13 Nov 2025
At a glance
- Originator Cloudbreak Pharma
- Class Alcohols; Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Cyclic ethers; Ethers; Eye disorder therapies; Heterocyclic compounds with 4 or more rings; Peripheral vasodilators; Pyrans; Urologics; Vascular disorder therapies
- Mechanism of Action ATP binding cassette transporter 1 stimulants; Cholesterol modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Meibomian gland dysfunction
Most Recent Events
- 13 Nov 2025 Chemical structure information added.
- 17 May 2022 Cloudbreak Pharma completes a phase II trial in Meibomian gland dysfunction in USA (Ophthalmic) (NCT04884243)
- 12 May 2021 Cloudbreak Pharma plans a phase II trial for Maeibomianitis, in June 2021 (NCT04884243)